Taiwan-developed novel ophthalmic drug enters 2nd clinical trial in U.S.

A novel ophthalmic drug developed by Taiwanese scientists using snake venom peptides has entered a second phase of human trials in the United States, according to the National Science and Technology Council (NSTC) on Tuesday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)